RCS - Thalia Therapeutics - New article: RNA medicine enters its second act

Thalia Therapeutics

09/06/2026 07:00

RNS Number : 4609H
  
Thalia Therapeutics PLC
  
09 June 2026
  
 


 
9 June 2026
 
Thalia Therapeutics plc
 
("Thalia" or the "Company")
 
New article: RNA medicine enters its second act
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA therapeutics, is pleased to share a new article, 'RNA medicine enters its second act', in European Biotechnology Magazine's RNA Therapeutics Special.
The RNA therapeutics market continues to gather momentum, presenting significant opportunities for innovation and value creation. Dr David Solomon, Chief Executive Officer of Thalia Therapeutics, discusses the Company's strategic focus on RNA therapeutics, the potential for new RNA modalities including microRNAs and the opportunity to address new therapeutic areas such as cardiovascular disease and oncology. 
Link to the article: https://issuu.com/biocom/docs/ebm_2026_rna_special?fr=sMjMyYTgzNTg2MzQ:  
- Ends -
 
 
For more information please contact:
 




Thalia Therapeutics plc
Dr David H Solomon, Chief Executive Officer


 
Via Thalia Investor Hub
https://investors.thaliatx.com/link/eWdkpr




SP Angel Corporate Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke/Josh Ray (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)


Tel: +44 (0)20 3470 0470




Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
Guy McDougall 


Tel: +44 (0)20 3657 0050




Northstar Communications
Investor relations and Communications
Sarah Hollins
 
Cohesion Bureau
Investor relations and Communications
Mary-Ann Chang


Tel: +44 (0)20 7183 2463
 
 
 
 
Tel: +44 (0)7483 284853
 
 
 




About Thalia Therapeutics plc
 
Thalia Therapeutics is a pre-clinical biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat diseases at the source by silencing or modifying the genes that cause or contribute to them.
 
Our preclinical bispecific siRNA is a potentially long-acting treatment for atherosclerotic cardiovascular disease, which addresses two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.
 
For further information visit www.thaliatx.com
 
 




This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRABUGDLLUGDGLI